Get started
Author

Linzhi Lu

A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China.
2021 · Zishao Zhong, Zhenyu Zhang, et al. · Europe PMC (PubMed Central) · 68
Alternate Integration of Vertically Oriented CuSe@FeOOH and CuSe@MnOOH Hybrid Nanosheets Frameworks for Flexible In-Plane Asymmetric Micro-supercapacitors
2020 · Jing-Chang Li, Jiangfeng Gong, et al. · ACS Applied Energy Materials · 51
Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer
2017 · Qinghong Guo, Xiaojun Liu, et al. · Medicine · 22
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study
2025 · Dan Liu, Jifang Gong, et al. · Signal Transduction and Targeted Therapy · 19
Risk factors in the development of gastric adenocarcinoma in the general population: A cross-sectional study of the Wuwei Cohort
2023 · Zhaofeng Chen, Ya Zheng, et al. · Frontiers in Microbiology · 18
PDF
Perioperative serplulimab with neoadjuvant chemotherapy versus perioperative chemotherapy in PD-L1-positive gastric cancer (ASTRUM-006): a randomised, double-blind, multicentre, phase 3 study
2026 · Lin Shen, Xiaotian Zhang, et al. · The Lancet · 16
A novel biotechnology for enhanced ciprofloxacin removal via bioaugmentation of Paraclostridium sp.
2022 · Heting Fang, Yanyan Jia, et al. · Bioresource Technology Reports · 14
Cohort Profile: A population-based cohort for the study of gastric cancer in northwest area of China (Wuwei Cohort)
2021 · Rui Ji, Zhiyi Zhang, et al. · International Journal of Epidemiology · 14
PDF
Association of single nucleotide polymorphisms (SNPs) with gastric cancer susceptibility and prognosis in population in Wuwei, Gansu, China
2022 · Ping Fan, Zhiyi Zhang, et al. · World Journal of Surgical Oncology · 13
PDF
Cholecystectomy is associated with a higher risk of irritable bowel syndrome in the UK Biobank: a prospective cohort study
2023 · Jinyu Zhao, Liang Tian, et al. · Frontiers in Pharmacology · 12
PDF
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
2025 · Lin Shen, Zhi Peng, et al. · Journal of Clinical Oncology · 10
PDF
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer
2024 · Ning Li, Meng Qiu, et al. · Med · 9
High incidence of gallstones after Roux-en-Y reconstruction gastrectomy in gastric cancer: a multicenter, long-term cohort study
2024 · Baoping Zhang, Peng Nie, et al. · International Journal of Surgery · 6
Gastric cancer‐associated long non‐coding RNA profiling and noninvasive biomarker screening based on a high‐risk population cohort
2023 · Xiaoying Guo, Yang Zhang, et al. · Cancer Medicine · 3
PDF
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (Chemo)/trastuzumab (Tra) for first-line (1L) HER2-expressing locally advanced or metastatic (la/m) gastric cancer (GC): Updated results from the RC48-C027 trial.
2026 · Zhi Peng, Changzheng Li, et al. · Journal of Clinical Oncology · 2
Circulating cell-free mtDNA fragmentomics for early detection of gastric cancer and precancerous lesions
2026 · Miao Dang, Siyuan Wang, et al. · Cell Reports Medicine · 2
Use of pronase in screening for early cancers of the upper gastrointestinal tract
2025 · Zhengqi Wu, Shihua Li, et al. · Hong Kong Medical Journal · 2
Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific antibody) intraperitoneal infusion in advanced epithelial solid tumor with malignant ascites vs paracentesis.
2026 · Jianming Xu, Yanqiao Zhang, et al. · Journal of Clinical Oncology · 1
Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
2026 · Lin Shen, Xiaotian Zhang, et al. · Journal of Clinical Oncology · 1
Updated results of HLX22 plus trastuzumab and XELOX for first-line treatment of human epidermal growth factor receptor 2 (HER2)–positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC).
2025 · Jin Li, Ning Li, et al. · Journal of Clinical Oncology · 1
PDF
HLX22 plus trastuzumab and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): Updated results with additional patients.
2025 · Jin Li, Ning Li, et al. · Journal of Clinical Oncology · 1
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
2024 · Jin Li, Yong Gao, et al. · Journal of Clinical Oncology · 1
PDF
Incidence, risk factors and tumor spectrum of second primary cancers after gastric cancer: a multicenter cohort study with long-term follow-up
2026 · Xianchun Gao, Weili Han, et al. · BMC Medicine
The association between blood lipid levels and the risk of atrophic gastritis: a cross-sectional study of the Wuwei cohort
2026 · Bowen Li, Jie Gao, et al. · Frontiers in Public Health
PDF
A phase Ib/IIa study of BAT8010+BAT1006, an anti-HER2 monoclonal antibody-exatecan conjugate combined with an ADCC-enhanced HER2 mAb in patients with advanced solid tumors: Results from the HER2-positive GC/GEJC cohort.
2026 · Xin Wang, Danyun Ruan, et al. · Journal of Clinical Oncology
PDF
Works count: 30
Citation count: 286
H-index: 10
I10-index: 11
Year
Topic
Type